Cargando…
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Autores principales: | Wardell, Suzanne E., Yllanes, Alexander P., Chao, Christina A., Bae, Yeeun, Andreano, Kaitlyn J., Desautels, Taylor K., Heetderks, Kendall A., Blitzer, Jeremy T., Norris, John D., McDonnell, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997263/ https://www.ncbi.nlm.nih.gov/pubmed/31734822 http://dx.doi.org/10.1007/s10549-019-05498-0 |
Ejemplares similares
-
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019) -
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020) -
Targeting mutant estrogen receptors
por: Wardell, Suzanne E, et al.
Publicado: (2019) -
Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004) -
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric
Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)